Disease relevance of AIDS-023790

• Kahalalide F, the only member of the family of peptides called kahalalides, isolated from the sacoglossan mollusc Elysia rufescens and the green alga Bryopsis sp., with important bioactivity, is in clinical trials for treatment of prostate cancer [1].
• In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells [2].
• The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines [3].
• No significant hemolysis due to the kahalalide F formulation as well as the CE vehicle was found using both a static and dynamic test model [4].
• Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells [5].

High impact information on AIDS-023790

• Kahalalide F (KF) is a novel marine-derived antitumor agent that is currently undergoing phase II clinical trials [6].
• Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling [6].
• The amino acid sequences of kahalalide R and S are proposed using collision-induced dissociation (CID) experiments of singly and doubly charged molecular ions and by comparison with the amino acid sequence of kahalalide F [7].
• Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry [8].
• Bryopsis sp. produces kahalalide F, a major depsipeptide that is accumulated by the sacoglossan and that shows in vitro cytotoxicity against several cancer cell lines [9].

Chemical compound and disease context of AIDS-023790

• PURPOSE: The purpose is to determine the maximum tolerated dose, profile of adverse events, and dose-limiting toxicity of Kahalalide F (KF) in patients with androgen refractory prostate cancer [10].

Biological context of AIDS-023790

• Biotransformations were not observed under these conditions and, therefore, it is concluded that kahalalide F is a metabolically stable drug [11].

Anatomical context of AIDS-023790

• The antitumoral compound Kahalalide F acts on cell lysosomes [12].
• The target for the antitumoral peptidic drug, Kahalalide F, has been studied in cultured cells [12].

Associations of AIDS-023790 with other chemical compounds

• Solubility and stability of kahalalide F were studied as a function of polysorbate 80 (0.1%-0.5% w/v) and citric acid monohydrate (15-15 mM) concentrations using an experimental design approach [13].
• Didemnin was the first marine peptide that entered in human clinical trials in US for the treatment of cancer, and other anticancer peptides such as kahalalide F, hemiasterlin, dolastatins, cemadotin, soblidotin, didemnins and aplidine have entered in the clinical trials [14].

Analytical, diagnostic and therapeutic context of AIDS-023790

• Spectra obtained using electrospray ionization mass spectrometry (ESI-MS) of the mollusk Elysia grandifolia showed a cluster of molecular ion peaks centered at a molecular mass of 1478 Da (kahalalide F, an anticancer agent) [7].

References